- socially bharat
- December 27, 2024
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Osaka, Japan & Cambridge, Mass., United States: HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the